Vuppalanchi, Raj

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis

Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 1,005

Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study

Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., et al. (2015) · Gastroenterology

Drug-Induced Hepatotoxicity and ProtectionPharmacovigilance and Adverse Drug Reactions

Cited by 925

Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network

Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology

Drug-Induced Hepatotoxicity and ProtectionComplementary and Alternative Medicine Studies

Cited by 418

Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension

Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 358

Therapeutic pipeline in nonalcoholic steatohepatitis

Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 278

High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population

Vilar‐Gomez, E., Nephew, L. D., Vuppalanchi, R., Gawrieh, S., Mladenovic, A., Pike, F., Samala, N., & Chalasani, N. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentNutritional Studies and Diet

Cited by 277

Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis

Vilar‐Gomez, E., Vuppalanchi, R., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2020) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 193

Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study

Huang, D. Q., Wilson, L. A., Behling, C., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Amangurbanova, M., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2023) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 190

Faecal microbiota transplantation plus selected use of vancomycin for severe‐complicated Clostridium difficile infection: description of a protocol with high success rate

Fischer, M., Sipe, B. W., Rogers, N. A., Cook, G. K., Robb, B. W., Vuppalanchi, R., & Rex, D. K. (2015) · Alimentary Pharmacology & Therapeutics

Clostridium difficile and Clostridium perfringens researchGut microbiota and health

Cited by 168

Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes

Vuppalanchi, R., Chalasani, N., & Teal, E. (2005) · The American Journal of the Medical Sciences

Drug-Induced Hepatotoxicity and ProtectionLiver Disease Diagnosis and Treatment

Cited by 133

Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease

Vuppalanchi, R., Jain, A. K., Deppe, R., Yates, K., Comerford, M., Masuoka, H. C., Neuschwander-Tetri, B. A., Loomba, R., Brunt, E. M., Kleiner, D. E., et al. (2014) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 116

Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

Vilar‐Gomez, E., Vuppalanchi, R., Desai, A. P., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2019) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentMetabolism, Diabetes, and Cancer

Cited by 84

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Vuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 79

Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system

Vilar-Gomez, E., Lou, Z., Kong, N., Vuppalanchi, R., Imperiale, T. F., & Chalasani, N. (2020) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 75

Significant dose-response association of physical activity and diet quality with mortality in adults with suspected NAFLD in a population study

Vilar-Gomez, E., Vuppalanchi, R., Gawrieh, S., Pike, F., Samala, N., & Chalasani, N. (2023) · American Journal of Gastroenterology

Liver Disease Diagnosis and TreatmentPhysical Activity and Health

Cited by 39

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

Murillo Perez, C. F., Ioannou, S., Hassanally, I., Trivedi, P. J., Corpechot, C., van der Meer, A. J., Lammers, W. J., Battezzati, P. M., Lindor, K. D., Nevens, F., et al. (2023) · Liver International

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39

Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials

Wong, V. W.-S., Tak, W. Y., Goh, G. B. B., Cheng, P.-N., Lawitz, E. J., Younossi, Z. M., Vuppalanchi, R., Younes, Z., Alkhouri, N., Wang, L., et al. (2023) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 31

Randomized Controlled Trial of a Leucine‐Metformin‐Sildenafil Combination (NS‐0200) on Weight and Metabolic Parameters

Zemel, M. B., Kolterman, O., Rinella, M., Vuppalanchi, R., Flores, O., Barritt, A. S., Siddiqui, M., & Chalasani, N. (2019) · Obesity

Pharmacology and Obesity TreatmentSirtuins and Resveratrol in Medicine

Cited by 19